ArticleJournal of clinical laboratory analysis2015
Impact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients.
Article in Journal of clinical laboratory analysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.Nutrients · 2025Pooled it
- Causal associations between environmental factors and risk of IgA nephropathy and membranous nephropathy: a bidirectional Mendelian randomization and mediation analysis.Renal failure · 2025Article
- Analysis of the impact of obesity on the prognosis of IgA nephropathy according to renal function and sex.Clinical and experimental nephrology · 2024Article
- Does Metabolic Syndrome and Its Components Have Prognostic Significance for Renal and Cardiovascular Outcomes in IgA Nephropathy?Biomedicines · 2024Article
- Article
- Evaluating Progression Risk in Patients With Immunoglobulin A Nephropathy.Kidney international reports · 2023Review
- The Impact of BMI Changes on the Incidence of Glomerular Hematuria in Korean Adults: A Retrospective Study Based on the NHIS-HEALS Cohort.Biomedicines · 2023Article
- Association of obesity with the development of end stage renal disease in IgA nephropathy patients.Frontiers in endocrinology · 2023Article
- Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients.Journal of molecular cell biology · 2021Article
- Outcome of 313 Czech Patients With IgA Nephropathy After Renal Transplantation.Frontiers in immunology · 2021Observational
- Emerging Modes of Treatment of IgA Nephropathy.International journal of molecular sciences · 2020Review
- The Impact of Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA Nephropathy.Journal of clinical medicine · 2020Article
- Clinical and histological features and therapeutic strategies for IgA nephropathy.Clinical and experimental nephrology · 2019Review
- Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases.BMC nephrology · 2019Article
- New strategies and perspectives on managing IgA nephropathy.Clinical and experimental nephrology · 2019Review
- Association of high body mass index with development of interstitial fibrosis in patients with IgA nephropathy.BMC nephrology · 2018Article
- Underweight Is an Independent Risk Factor for Renal Function Deterioration in Patients with IgA Nephropathy.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of being overweight remains unclear in Asian populations that tend to be lean. The objective of this study is to clarify the impact of body mass index (BMI) and metabolic factors on the prognosis of Japanese patients with IgA nephropathy (IgAN).
methodsA total of 193 patients with IgAN were divided into three groups equally according to BMI: Group L (lean group, BMI: 15.6-20.1 kg/m(2) ), Group M (middle group, BMI: 20.2-23.0 kg/m(2) ), and Group O (obesity group, BMI: 23.1-31.9 kg/m(2) ). Clinical data at the time of renal biopsy and the progression of the patients after renal biopsy were analyzed.
resultsAt the time of renal biopsy, hypertension, dyslipidemia, hyperuricemia, and hypercomplementemia in Group O were more significant compared with those in Group L and/or Group M. Uric acid, triglyceride, C3, C4, high-density lipoprotein cholesterol, serum creatinine, systolic blood pressure (BP), and diastolic BP were significantly correlated with BMI. In Group O, the remission of urinary protein over 5 years was significantly delayed using a log-rank test. At the final observation, the BMI of each group was as similar as that at renal biopsy. The patients with aggressive therapy, such as steroid therapy and/or tonsillectomy in Group O did not have major side effects, except for a slight elevation of total cholesterol and low-density lipoprotein cholesterol.
conclusionEven slightly high BMI seems to be a risk factor for progress in Japanese patients with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.